Pharming Group N.V. (PHAR)

Pharming Group Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	51.89	61.74	207.56	192.15	206.15	74.35
Short-Term Investments	150.08	151.68	0	0	0	0
Cash & Cash Equivalents	201.97	213.42	207.56	192.15	206.15	74.35
Cash Growth	9.17%	2.83%	8.02%	-6.79%	177.28%	-7.42%
Receivables	38.7	46.16	27.62	29.98	35.9	28.86
Inventory	55.88	56.76	42.33	27.31	21.16	16.22
Total Current Assets	296.55	316.34	277.5	249.44	263.21	119.44
Property, Plant & Equipment	31.86	33.47	39.15	33.17	21.65	16.3
Long-Term Investments	9.18	11.93	10.83	9.46	7.63	8.72
Goodwill and Intangibles	68.3	71.27	75.12	83.83	94.08	79.4
Other Long-Term Assets	35.78	29.85	23.2	21.41	31.88	32.06
Total Long-Term Assets	145.12	146.51	148.3	147.87	155.24	136.48
Total Assets	441.67	462.85	425.8	397.32	418.45	255.92
Accounts Payable	68.52	72.53	54.47	42.47	47.67	40.65
Current Debt	138.77	5.44	5.23	4.3	29	73.31
Other Current Liabilities	0	0	0	0	0.18	0.3
Total Current Liabilities	207.29	77.97	59.7	46.77	76.85	114.25
Long-Term Debt	28.44	166.11	161.46	157.63	158.17	24.27
Total Long-Term Liabilities	28.44	166.11	161.46	157.63	158.17	24.27
Total Liabilities	235.72	244.07	221.16	204.4	235.02	138.53
Total Debt	167.21	171.55	166.69	161.93	187.17	97.58
Debt Growth	-1.87%	2.91%	2.94%	-13.49%	91.81%	-20.31%
Retained Earnings	-277.39	-265.26	-256.43	-273.17	-295.62	-340.72
Shareholders' Equity	205.95	218.78	204.64	192.92	183.44	117.39
Net Cash / Debt	34.76	41.88	40.86	30.23	18.98	-23.23
Net Cash / Debt Growth	138.12%	2.49%	35.19%	59.22%	-	-
Working Capital	89.27	238.37	217.8	202.67	186.36	5.18
Book Value Per Share	3.07	3.32	3.15	3.02	2.88	1.84

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).